Is tirzepatide really better than Ozempic for weight loss?

Phase 3 SURMOUNT-1 peak was -22.5% body weight at 15mg/wk over 72 weeks for tirzepatide (Jastreboff et al, NEJM 2022). Phase 3 STEP-1 peak was -14.9% at 2.4mg/wk over 68 weeks for semaglutide / Wegovy (Wilding et al, NEJM 2021). The 7.6 percentage-point gap is a data observation across separate trials with different cohorts, different sponsors, different durations. The SURPASS-2 trial was head-to-head between tirzepatide and semaglutide, but in TYPE 2 DIABETES at lower doses (tirz 15mg vs sema 1mg, 40 weeks), useful as a directional signal but not an obesity head-to-head.

Are Mounjaro and Zepbound the same as tirzepatide?

Yes. Both are brand-name tirzepatide manufactured by Eli Lilly. Mounjaro was FDA-approved May 2022 for type 2 diabetes with a maximum dose of 15mg/wk. Zepbound was FDA-approved November 2023 specifically for chronic weight management in adults with BMI of 30 or higher (or 27 with a comorbidity), same 15mg/wk maximum. Same molecule, different on-label indications.

Are Ozempic and Wegovy the same as semaglutide?

Yes. Both are brand-name semaglutide from Novo Nordisk. Ozempic was FDA-approved December 2017 for type 2 diabetes (max 2mg/wk). Wegovy was FDA-approved June 2021 for chronic weight management (max 2.4mg/wk). Same molecule, different titration ceiling, different on-label indications.

Why is Peptara tirzepatide so much cheaper than the brand pens?

At starting doses the gap is roughly 10 to 15x (Peptara $85/mo first-time at 2.5mg/wk vs Wegovy $1,349/mo). At peak doses it narrows to roughly 2 to 3x (Peptara $510/mo first-time at 15mg/wk vs Wegovy $1,349/mo). Two reasons. First, format: Peptara ships a freeze-dried research vial that the user reconstitutes with bac water. Brand pens are pre-filled finished pharmaceuticals with cold-chain logistics, FDA-approval-grade quality assurance, pharmacy distribution, and Novo Nordisk / Eli Lilly margin. Second, market: Peptara serves international research customers, not the US prescription market. The molecule is the same; the regulatory pathway and supply chain are not.

Does Peptara sell Ozempic or Wegovy?

No. Peptara does NOT sell semaglutide in any form. Peptara is a research-peptide supplier; brand pens are finished pharmaceuticals available only via prescription. Anyone selling "Wegovy from Vietnam" online is selling gray-market product with no chain-of-custody guarantee. Peptara stocks Tirzepatide as a research vial (the same molecule as Mounjaro / Zepbound), not as a brand pen.

What are the side effects of tirzepatide vs semaglutide?

Both share the GLP-1 class side-effect profile: nausea, diarrhea, constipation, vomiting. Most pronounced during titration and at higher doses; usually resolve over 4 to 8 weeks at a given dose. SURMOUNT-1 reported nausea in roughly 30% at peak 15mg/wk tirzepatide vs roughly 10% placebo. Semaglutide has the longer safety record (SUSTAIN cardiovascular outcomes trial in T2D, SELECT cardiovascular trial in obesity). Both carry the GLP-1 class thyroid C-cell black-box warning (rodent signal; no confirmed human cases).

Can I switch from Ozempic to tirzepatide?

This is a medical decision and should be discussed with a licensed physician. Do not stop FDA-approved therapy without consulting the prescribing doctor. Peptara does not provide medical advice and does not recommend any specific switch protocol. Generally, users who switch wait until their next dose cycle would have started before introducing the new compound, and titrate the new compound from a low starting dose.

How does this compare to retatrutide?

Retatrutide is a triple-agonist (GLP-1 + GIP + glucagon) currently in Phase 3 (TRIUMPH program, Eli Lilly). Phase 2 peak was -24.2% body weight at 12mg/wk over 48 weeks (Jastreboff et al, NEJM 2023). Larger trial effect than both tirzepatide and semaglutide, but Phase 3 data is still being collected and retatrutide is not yet FDA-approved. See the Retatrutide vs Tirzepatide and Retatrutide vs Ozempic comparison pages for the full breakdowns.

Head to head

Tirzepatide vs Ozempic: 22% vs 15% Fat Loss

Mounjaro / Zepbound (tirzepatide) vs Ozempic / Wegovy (semaglutide). Both FDA-approved as brand pens. Tirzepatide is a dual-agonist (GLP-1 + GIP); semaglutide is single-agonist GLP-1. Different trials, not head-to-head in obesity.

Verdict in 4 lines

Tirzepatide hit -22.5% body weight in SURMOUNT-1 (Phase 3, 72 weeks).
Semaglutide hit -14.9% in STEP-1 (Phase 3, 68 weeks).
Different trials, different cohorts. Treat the gap as a data observation, not a head-to-head finding.
Peptara sells Tirzepatide as a research vial ($85 to $510/mo). Peptara does NOT sell semaglutide. US brand pen retail: Ozempic about $968/mo, Wegovy about $1,349/mo.

TL;DR comparison

One table, every row that matters. Tirzepatide dose values use units from a U-100 insulin syringe with the Peptara standard reconstitution (20mg vial in 2mL bac water, 200 units per vial, 0.1mg per unit). Semaglutide dose values are the brand pre-filled pen ladder (no reconstitution required). See the reconstitution guide for the tirzepatide math.

Tirzepatide

Ozempic / Wegovy (semaglutide)

Class

Dual agonist (GLP-1 + GIP)

Single agonist (GLP-1 only)

Mechanism

Activates two appetite + metabolic receptors

Activates one appetite receptor (GLP-1)

FDA status

Mounjaro FDA-approved 2022 (T2D). Zepbound FDA-approved 2023 (obesity).

Ozempic FDA-approved 2017 (T2D). Wegovy FDA-approved 2021 (obesity).

Trial peak weight loss

-22.5% at 15mg/wk, Phase 3 SURMOUNT-1, 72 weeks (NEJM 2022)

-14.9% at 2.4mg/wk, Phase 3 STEP-1, 68 weeks (NEJM 2021)

Manufacturer

Eli Lilly

Novo Nordisk

Format sold

Brand pre-filled pens (Mounjaro / Zepbound via prescription); research vials (Peptara: 20mg lyo vial)

Brand pre-filled pens (Ozempic / Wegovy via prescription)

Standard recon

2mL bac water gives 200u/vial, 0.1mg/u

Pre-titrated pen (no recon)

Weekly dose

Titrate 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg over months (25u, 50u, 75u, 100u, 125u, 150u)

Titrate 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg pen (Wegovy schedule)

Cost / month

about $85 to $510 via Peptara first-time

about $968 (Ozempic) to $1,349 (Wegovy) US retail cash list

Side effects

GI (nausea, diarrhea), dose-dependent. SURMOUNT-1 trial well-characterized.

GI (nausea, diarrhea), well-characterized over years of clinical use

Access in Vietnam

Peptara stocks Tirzepatide locally

Ozempic / Wegovy not officially imported. Require prescription where available.

Mechanism: dual GLP-1 + GIP vs single GLP-1

Both compounds activate the GLP-1 satiety and insulin axis. Tirzepatide adds a second receptor.

Tirzepatide (dual agonist)

Targets two receptor systems: the standard GLP-1 satiety and insulin axis (slows gastric emptying, reduces appetite) plus GIP (glucose-dependent insulinotropic polypeptide), which appears to add fat-mass-loss benefit on top of GLP-1 alone. Sold as Mounjaro (T2D, FDA 2022) and Zepbound (obesity, FDA 2023) brand pens, and as a research vial by Peptara.

View Tirzepatide product

Semaglutide (single GLP-1 agonist)

Targets one receptor system (GLP-1 only). Mature clinical data spans more than 10 years through Ozempic and Wegovy trials, including SUSTAIN (T2D cardiovascular) and SELECT (obesity cardiovascular outcomes). Sold as Ozempic (T2D, FDA 2017) and Wegovy (obesity, FDA 2021) brand pens. Peptara does not sell semaglutide.

Honest trade-off: more receptor activation drives a stronger fat-loss signal in Phase 3 trials, but semaglutide has the longer real-world safety record. For the GLP-1 + GIP + glucagon triple-agonist (Retatrutide), see Retatrutide vs Tirzepatide.

Clinical trial results

Headline figures, trial citations, and the disclaimer that has to come with them.

Tirzepatide Phase 3 (SURMOUNT-1)

Reference: Jastreboff et al, NEJM 2022;387(3):205-216
Phase: 3
n: 2,539 (no T2D)
Duration: 72 weeks
15mg/wk: -22.5% mean body weight
10mg/wk: -22.2% · 5mg/wk: -16.1% · Placebo: -2.4%

Semaglutide Phase 3 (STEP-1)

Reference: Wilding et al, NEJM 2021;384(11):989-1002
Phase: 3
n: 1,961 (no T2D)
Duration: 68 weeks
2.4mg/wk: -14.9% mean body weight
Placebo: -2.4%. Trial supported the 2021 Wegovy FDA approval.

Read this before quoting either number

Different trials, not head-to-head in obesity. SURMOUNT-1 ran 72 weeks; STEP-1 ran 68 weeks. Different cohorts, different sponsors, different placebo response calibration. The 7.6 percentage-point gap is a data observation across trials, not a controlled head-to-head finding.

Note on SURPASS-2 (Frias et al, NEJM 2021): this was a head-to-head trial between tirzepatide and semaglutide, but in TYPE 2 DIABETES (not obesity) at lower doses (tirzepatide 15mg vs semaglutide 1mg, 40 weeks). At those doses tirzepatide reduced body weight 11.2kg vs semaglutide 5.7kg. Useful directional signal, but the patient population is T2D and the semaglutide dose ceiling was the T2D-label 1mg. SURPASS-2 is not a head-to-head obesity comparison.

FDA and regulatory status

Both compounds are FDA-approved as brand pens. This is the symmetric case in the /vs/* cluster. The asymmetry is format: brand pens vs research vial.

Tirzepatide brand pens (Eli Lilly)

Mounjaro: FDA-approved May 13, 2022. Indication: type 2 diabetes. Max dose 15mg/wk.
Zepbound: FDA-approved Nov 8, 2023. Indication: chronic weight management. Max dose 15mg/wk.

Semaglutide brand pens (Novo Nordisk)

Ozempic: FDA-approved Dec 5, 2017. Indication: type 2 diabetes. Max dose 2mg/wk.
Wegovy: FDA-approved Jun 4, 2021. Indication: chronic weight management. Max dose 2.4mg/wk.

Peptara format and scope

Peptara stocks Tirzepatide as a RESEARCH compound (vial format) for international research customers. The brand pens (Mounjaro, Zepbound, Ozempic, Wegovy) are FDA-approved finished pharmaceuticals available only via prescription in their approved markets. Peptara does not sell brand pens and does not sell semaglutide in any form.

Side effects

Both share the GI-dominant GLP-1 class profile. Notes below are not exhaustive.

Shared (GLP-1 class)

Nausea, most pronounced during titration
Diarrhea
Constipation
Vomiting at higher doses
Typically resolve over 4 to 8 weeks at a given dose

Semaglutide-specific

Years of clinical safety data (SUSTAIN, SELECT)
FDA black-box warning: thyroid C-cell tumors (rodent data)
Gastroparesis case reports at high cumulative exposure
Rare pancreatitis and gallbladder events

Tirzepatide-specific

SURMOUNT-1: nausea about 30% at 15mg vs about 10% placebo
Lower hypoglycemia risk than insulin combinations (T2D context)
Same GLP-1 class thyroid C-cell black-box warning
Dual agonism may amplify early-week GI in some users

Mitigation for both: titrate slowly from the lowest starting dose, inject at the same time each week to stabilize blood levels, hydrate aggressively during the first 2 weeks of any new dose step. Stop and consult a licensed physician for severe or persistent GI symptoms, signs of pancreatitis, or any unusual side effect.

Dosing protocols

Tirzepatide via Peptara is dosed in U-100 syringe units (research vial format). Semaglutide is sold as a pre-titrated pen, no unit math required. Both titrate slowly from the lowest dose.

Tirzepatide via Peptara (units)

20mg vial, 200u total, 0.1mg per unit

Weeks 1 to 4: 2.5mg/wk = 25 units
Weeks 5 to 8: 5mg/wk = 50 units
Weeks 9 to 12: 7.5mg/wk = 75 units
Weeks 13 to 16: 10mg/wk = 100 units
Weeks 17 to 20: 12.5mg/wk = 125 units (may split across days for syringe capacity)
Weeks 21 plus: 15mg/wk = 150 units (1 vial lasts about 1.33 weeks at peak)

Units only. Dose on a U-100 insulin syringe. 1 unit equals 0.01mL equals 0.1mg at this concentration. Never measure dose in mL.

See /reconstitution for the underlying U-100 math.

Semaglutide (brand pen)

Wegovy FlexTouch pre-filled pen, pre-titrated, no reconstitution

Month 1: 0.25mg/wk (red pen)
Month 2: 0.5mg/wk (yellow pen)
Month 3: 1mg/wk (blue pen)
Month 4: 1.7mg/wk (purple pen)
Month 5 plus: 2.4mg/wk maintenance (green pen)

Ozempic caps at 2mg/wk (T2D label). Wegovy goes to 2.4mg/wk (obesity label). Both require a prescription. Peptara does not sell semaglutide.

Cost per month

Tirzepatide cost is derived from Peptara vial price using the formula: cost per month equals vial price times 4.33 weeks per month, divided by weeks per vial. Semaglutide cost is quoted from US retail / compounding pharmacy reference points, not Peptara pricing.

Tirzepatide via Peptara

$157 first-time per 20mg vial ($185 retail). weeks per vial = 20mg / weekly dose in mg.

Dose	Weeks/vial	First-time	Retail
2.5mg/wk (start)	8 wk	about $85/mo	about $100/mo
5mg/wk	4 wk	about $170/mo	about $200/mo
7.5mg/wk	2.67 wk	about $255/mo	about $300/mo
10mg/wk	2 wk	about $340/mo	about $401/mo
12.5mg/wk	1.6 wk	about $425/mo	about $501/mo
15mg/wk (peak)	1.33 wk	about $510/mo	about $601/mo

Semaglutide US retail (external reference)

External reference pricing only. Peptara does NOT sell semaglutide.

Ozempic (Novo Nordisk cash list): 0.5 to 2mg/wk, about $968/mo US retail
Wegovy (Novo Nordisk cash list): 0.25 to 2.4mg/wk, about $1,349/mo US retail
Compounded semaglutide: 0.25 to 2.4mg/wk, about $200 to $400/mo (FDA-restricted after October 2024 shortage resolution; legal availability shrinking)

Vietnam reality check

Ozempic and Wegovy are not officially imported into Vietnam. Gray-market pens circulate at $500 to $1,500/mo with no chain-of-custody guarantee. Peptara does NOT source gray-market semaglutide. Local prescription access is limited.

Headline cost delta

Tirzepatide via Peptara at peak 15mg/wk dose: $510/mo first-time, $601/mo retail. Wegovy US retail at peak 2.4mg/wk: $1,349/mo. At peak dose Tirzepatide via Peptara is roughly 55 to 62% cheaper than Wegovy (depending on first-time vs retail tier). At starting doses the gap widens to roughly 10 to 15x cheaper (Peptara $85 first-time vs Wegovy $1,349 / Ozempic $968). Format and regulatory pathway are fundamentally different: Peptara sells a research vial, whereas Wegovy and Ozempic are FDA-approved finished pharmaceuticals via prescription.

Who picks which

Three short profiles. No single right answer, just trade-offs that map to user context.

Pick Wegovy / Ozempic if

You want an FDA-approved obesity drug via prescription
Your insurance covers it (or you accept $968 to $1,349/mo cash)
You want the longest-duration safety record (SELECT cardiovascular)
You prefer a pre-filled pen with no reconstitution

Pick Tirzepatide via Peptara if

You accept a research-vial protocol (units on syringe)
You want the larger Phase 3 trial effect (-22.5% vs -14.9%)
You want the lower-cost path (about $85 to $510/mo)
You are outside the US Rx market for brand pens

Pick Retatrutide if

You want the LARGEST trial effect (-24.2% Phase 2 at 12mg/wk)
You accept Phase 3 data is still being collected
You are already comfortable with the research-vial format
See Retatrutide vs Tirzepatide and Retatrutide vs Ozempic for the reta comparisons

Frequently asked questions

Next steps

Buy Tirzepatide via Peptara

20mg vial, $157 first-time / $185 retail. Same molecule as Mounjaro / Zepbound, research-vial format. Ships from HCMC with COA on request.

View product

How to reconstitute your vial

4-step method, units-not-mL math, calculator for all 15 SKUs. Required reading before your first tirzepatide injection.

Open guide

Retatrutide vs Tirzepatide

Triple vs dual agonist, Phase 2 -24.2% vs Phase 3 -22.5% trial peaks. The next-generation comparison side by side.

Open comparison

Retatrutide vs Ozempic →Full FAQ →About Peptara →

Questions on tirzepatide vs Ozempic

Questions about tirzepatide vs Ozempic? Message the Peptara team on WhatsApp. We answer protocol questions, not medical questions.

Every Tirzepatide order ships with bac water sized to the vial, a custom dashboard with your doses in units (never mL), and ongoing protocol support.

Chat on WhatsApp Browse all 15 peptides →